Product Development Partnerships like MMV are contributing in important ways to the global effort against COVID-19.
Over recent years MMV has developed end-to-end capabilities spanning drug discovery, development and delivery, that have brought new malaria medicines to millions in need. Now these capabilities are more crucial than ever. Early on MMV adapted its work plan for anticipated pandemic-related delays, while accelerating other areas of work to ensure that we could emerge with the strongest possible malaria portfolio. In parallel, MMV also reprioritized its areas of strategic focus for 2020 to include support for the COVID-19 effort.
Below you will find resources on MMV's activities in the context of COVID-19 as well as partner content on COVID-19 and malaria.